Carlsmed, Inc. has filed a patent infringement lawsuit against DeGen Medical, seeking damages and injunctive relief.
Quiver AI Summary
Carlsmed, Inc., a company specializing in AI-enabled personalized spine surgery solutions, has filed a patent infringement lawsuit against DeGen Medical, Inc. in the U.S. District Court for the District of South Carolina. The lawsuit claims that DeGen is infringing on eight of Carlsmed's patents related to its surgical implants and methods. Carlsmed is pursuing both injunctive relief and damages. CEO Mike Cordonnier emphasized the company's commitment to advancing spine surgery standards through innovative solutions and protecting its intellectual property. Carlsmed's mission is to improve healthcare outcomes and reduce costs in spine surgery.
Potential Positives
- Carlsmed is actively protecting its intellectual property by filing a patent infringement lawsuit, which demonstrates the company's commitment to its innovations and proprietary technology.
- The lawsuit targets eight patents related to its personalized spine surgery solutions, highlighting the strength and breadth of Carlsmed's portfolio in the medical technology field.
- The company aims to seek injunctive relief and damages, which could potentially lead to significant financial benefits if successful.
- Carlsmed emphasizes its mission to improve healthcare outcomes and reduce costs in spine surgery, reinforcing its dedication to innovation and patient care, which may attract positive attention from stakeholders.
Potential Negatives
- Filing a patent infringement lawsuit may signal potential legal liabilities and costs, which could divert resources and attention from core business operations.
- The lawsuit against DeGen Medical could lead to a prolonged legal battle, which may deter potential investors or partners worried about the company's legal challenges.
- The need to protect intellectual property through litigation may indicate vulnerabilities in Carlsmed's competitive position in the market.
FAQ
What lawsuit did Carlsmed recently file?
Carlsmed filed a patent infringement lawsuit against DeGen Medical for infringing eight of its patents related to spine surgery solutions.
What is the aim of Carlsmed's lawsuit?
Carlsmed seeks injunctive relief and damages for the alleged infringement of its proprietary technologies.
Who is the CEO of Carlsmed?
Mike Cordonnier is the Chairman and CEO of Carlsmed, emphasizing the company's commitment to innovation in spine surgery.
What technologies does Carlsmed specialize in?
Carlsmed specializes in AI-enabled personalized spine surgery solutions, aiming to improve healthcare outcomes and reduce costs.
How does Carlsmed protect its innovations?
Carlsmed protects its innovations through patents and is committed to safeguarding its intellectual property against infringement.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CARL Hedge Fund Activity
We have seen 53 institutional investors add shares of $CARL stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ORBIMED ADVISORS LLC removed 1,252,600 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $13,001,988
- PIER CAPITAL, LLC added 373,677 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,878,767
- MILLENNIUM MANAGEMENT LLC added 295,907 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,071,514
- PALUMBO WEALTH MANAGEMENT LLC added 267,298 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,774,553
- KCM CAPITAL INC added 240,000 shares (+120.0%) to their portfolio in Q2 2026, for an estimated $2,491,200
- TEACHER RETIREMENT SYSTEM OF TEXAS removed 175,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,583,750
- AQR CAPITAL MANAGEMENT LLC added 92,159 shares (+inf%) to their portfolio in Q2 2026, for an estimated $956,610
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CARL Analyst Ratings
Wall Street analysts have issued reports on $CARL in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 05/06/2026
To track analyst ratings and price targets for $CARL, check out Quiver Quantitative's $CARL forecast page.
$CARL Price Targets
Multiple analysts have issued price targets for $CARL recently. We have seen 4 analysts offer price targets for $CARL in the last 6 months, with a median target of $17.5.
Here are some recent targets:
- David Saxon from Needham set a target price of $17.0 on 07/01/2026
- Ryan Zimmerman from BTIG set a target price of $23.0 on 05/06/2026
- Richard Newitter from Truist Securities set a target price of $18.0 on 04/15/2026
- David Roman from Goldman Sachs set a target price of $17.0 on 04/09/2026
Full Release
CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed a patent infringement lawsuit against DeGen Medical, Inc. (“DeGen”) in the United States District Court for the District of South Carolina Florence Division.
The complaint asserts that DeGen is infringing eight of Carlsmed’s patents relating to its implants, methods and systems. Carlsmed is seeking injunctive relief and damages for infringement.
“Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing value to patients, surgeons, and payors every day. We are committed to protecting the intellectual property that supports our patient-centric innovation, which remains at the forefront of the industry,” said Mike Cordonnier, Chairman and CEO of Carlsmed.
About Carlsmed, Inc.
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about Carlsmed’s ability to scale its business and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Annual Report on Form 10-K on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.
Investor Relations
[email protected]
Media
[email protected]